AU2020290516B2 - Compositions and methods for biological delivery vehicles - Google Patents

Compositions and methods for biological delivery vehicles

Info

Publication number
AU2020290516B2
AU2020290516B2 AU2020290516A AU2020290516A AU2020290516B2 AU 2020290516 B2 AU2020290516 B2 AU 2020290516B2 AU 2020290516 A AU2020290516 A AU 2020290516A AU 2020290516 A AU2020290516 A AU 2020290516A AU 2020290516 B2 AU2020290516 B2 AU 2020290516B2
Authority
AU
Australia
Prior art keywords
delivery vehicle
lipid
mole
glycero
cationic lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020290516A
Other languages
English (en)
Other versions
AU2020290516A1 (en
AU2020290516A2 (en
Inventor
Mubhij AHMAD
Timothy Day
Ismail Hafez
John Merritt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Particella Inc
Original Assignee
Dnalite Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnalite Therapeutics Inc filed Critical Dnalite Therapeutics Inc
Publication of AU2020290516A1 publication Critical patent/AU2020290516A1/en
Publication of AU2020290516A2 publication Critical patent/AU2020290516A2/en
Application granted granted Critical
Publication of AU2020290516B2 publication Critical patent/AU2020290516B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909Micelles formed by phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020290516A 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles Active AU2020290516B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861852P 2019-06-14 2019-06-14
US62/861,852 2019-06-14
US201962948095P 2019-12-13 2019-12-13
US62/948,095 2019-12-13
PCT/US2020/037579 WO2020252375A1 (en) 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles

Publications (3)

Publication Number Publication Date
AU2020290516A1 AU2020290516A1 (en) 2022-01-20
AU2020290516A2 AU2020290516A2 (en) 2022-03-31
AU2020290516B2 true AU2020290516B2 (en) 2026-01-29

Family

ID=73781318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020290516A Active AU2020290516B2 (en) 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles

Country Status (8)

Country Link
US (1) US20220296516A1 (https=)
EP (1) EP3982932A4 (https=)
JP (1) JP7772597B2 (https=)
CN (1) CN114286671A (https=)
AU (1) AU2020290516B2 (https=)
CA (1) CA3142949A1 (https=)
IL (1) IL288755A (https=)
WO (1) WO2020252375A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) * 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems
US20240050477A1 (en) * 2021-02-17 2024-02-15 National University Corporation Hokkaido University Lipid nanoparticle
US20240358651A1 (en) * 2021-04-01 2024-10-31 Snj Pharma Inc Oral nanoparticles for bioactive compound, and method of preparing same
KR102789632B1 (ko) * 2021-04-01 2025-04-01 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
KR20230141513A (ko) * 2022-03-22 2023-10-10 주식회사 바이오엔 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도
CN117247359A (zh) * 2022-06-09 2023-12-19 中国科学院广州生物医药与健康研究院 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN118356505A (zh) * 2023-01-10 2024-07-19 复旦大学 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途
CN121443279A (zh) * 2023-06-28 2026-01-30 环球生命科学解决方案加拿大有限公司 用于细胞疗法的脂质纳米颗粒制剂和相关方法
WO2025021286A1 (en) * 2023-07-23 2025-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. A drug delivery system for increased endosomal escape
CN121752254A (zh) * 2023-08-11 2026-03-27 浙江海昶生物医药股份有限公司 一种具有靶向性的脂质组合物及其制备方法
US20250082776A1 (en) * 2023-08-31 2025-03-13 Massachusetts Institute Of Technology Polyanion coated lipid nanoparticles and methods of use thereof
PL248770B1 (pl) * 2023-11-23 2026-01-26 Politechnika Wroclawska Bilosomy o dodatnim ładunku i sposób ich wytwarzania
WO2025151073A1 (en) * 2024-01-10 2025-07-17 Agency For Science, Technology And Research Composition and nanoparticle suitable for use in the delivery of a therapeutic agent

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239657A1 (en) * 2006-11-09 2010-09-23 Mogam Biotechnology Research Institute Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011075656A1 (en) * 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2012113803A1 (en) * 2011-02-22 2012-08-30 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
WO2016070082A1 (en) * 2014-10-31 2016-05-06 University Of Utah Research Foundation Compositions and methods for bile acid particles
WO2018078053A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509387A (ja) * 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
EP3675817A1 (en) * 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239657A1 (en) * 2006-11-09 2010-09-23 Mogam Biotechnology Research Institute Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011075656A1 (en) * 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2012113803A1 (en) * 2011-02-22 2012-08-30 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
WO2016070082A1 (en) * 2014-10-31 2016-05-06 University Of Utah Research Foundation Compositions and methods for bile acid particles
WO2018078053A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JITINDER S WIKHU , SARAH E MCNEIL , DAVID E ANDERSON , YVONNE PERRIE : "Characterization and optimization of bilosomes for oral vaccine delivery", JOURNAL OF DRUG TARGETING, TAYLOR & FRANCIS, GB, vol. 21, no. 3, 30 November 2012 (2012-11-30), GB, pages 291 - 299, XP009532436, ISSN: 1061-186X, DOI: 10.3109/1061186X.2012.747528 *
MONALISA MOHAPATRA, ASHOK K. MISHRA: "Effect of Submicellar Concentrations of Conjugated and Unconjugated Bile Salts on the Lipid Bilayer Membrane", LANGMUIR, AMERICAN CHEMICAL SOCIETY, vol. 27, no. 22, 15 November 2011 (2011-11-15), pages 13461 - 13467, XP055771017, ISSN: 0743-7463, DOI: 10.1021/la203028s *
SCHWENDENER RETO A.: "Liposomes as vaccine delivery systems: a review of the recent advances", THER ADV VACCINES, 1 January 2014 (2014-01-01), pages 159 - 182, XP055874534, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/2051013614541440> [retrieved on 20211220], DOI: 10.1177/2051013614541440Therapeutic *
TANVI RAJPUT, TANVI RAJPUT, MEENAKSHI CHAUHAN: "BILOSOME: A BILE SALT BASED NOVEL CARRIER SYSTEM GAINING INTEREST IN PHARMACEUTICAL RESEARCH", JOURNAL OF DRUG DELIVERY AND THERAPEUTICS, VINITA NAGAR, vol. 7, no. 5, 15 September 2017 (2017-09-15), pages 4 - 16, XP055771018, ISSN: 2250-1177, DOI: 10.22270/jddt.v7i5.1479 *

Also Published As

Publication number Publication date
JP7772597B2 (ja) 2025-11-18
WO2020252375A1 (en) 2020-12-17
JP2022538797A (ja) 2022-09-06
AU2020290516A1 (en) 2022-01-20
CN114286671A (zh) 2022-04-05
AU2020290516A2 (en) 2022-03-31
IL288755A (en) 2022-02-01
EP3982932A1 (en) 2022-04-20
EP3982932A4 (en) 2023-10-25
US20220296516A1 (en) 2022-09-22
CA3142949A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
AU2020290516B2 (en) Compositions and methods for biological delivery vehicles
US20230023615A1 (en) Compositions and methods for biological delivery vehicles
WO2022260678A1 (en) Compositions and methods for biological delivery vehicles
JP3907662B2 (ja) 自己構築ポリヌクレオチド送達システム
JP2021050212A (ja) 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
US20240058454A1 (en) Biological delivery systems
TW201019969A (en) Branched cationic lipids for nucleic acids delivery system
US20190351071A1 (en) Structures and methods for gene therapy
US20240197636A1 (en) Tissue-specific nucleic acid delivery by mixed cationic lipid particles
US20210177982A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
US20250041325A1 (en) Lipid-based compositions and methods thereof
KR20250134181A (ko) 핵산의 표적화된 전달을 위한 상승된 중성 지질 및 표적화 모이어티를 포함하는 지질 나노입자
US20240269318A1 (en) Nano-delivery systems comprising modified lipids and use thereof
US20160038597A9 (en) Carrier that targets fucosylated molecule-producing cells
JP5615509B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
CN117241780A (zh) 生物递送系统
JP5871247B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
KR20250141812A (ko) Rna에 대한 선천성 면역 반응을 감소시키기 위한 방법 및 변형

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 14 MAR 2022